| | | |   | | | | By Matthew Herper and Damian Garde and Adam Feuerstein Michel Euler/AP Viehbacher, 62, will take the reins Monday, succeeding CEO Michel Vounatsos, who announced his impending resignation in May. Read More | | By Matthew Herper Adobe The company's announcement stands in stark contrast to the approach it indicated it would take three years ago. Read More | | By Allison DeAngelis Jessica Rinaldi/The Boston Globe Jonas’ next step came to light on Thursday, when CBC announced that it has hired Jonas to lead a new biotech incubator called ABiox-X. Read More | | Sponsored Insight by TriNetX, LLC. From months to minutes: the need for speed in real-world evidence generation The process of identifying, acquiring, and evaluating the right real-world data, not to mention converting that data into evidence, is rife with failure and delay. It’s time for eClinical innovators to step up with a single, self-service trusted research environment that unites continuously refreshed RWD with a flexible coding environment. Read what that solution needs to deliver, from cohort definition to computational power. | | By Adam Feuerstein Spencer Platt/Getty Images Seagen has named pharmaceutical industry executive David Epstein as its new leader to replace Clay Siegall, who resigned in May Read More | | By Megan Molteni Adobe The Phase 1 trial found that the personally formulated gene-edited immune cells didn’t cure patients, but they didn’t kill anyone either. Read More | | By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine. Read More | |
No comments